` O2T (Iveric Bio Inc) vs DAX Index Comparison - Alpha Spread

I
O2T
vs
D
DAX Index

Over the past 12 months, O2T has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +22% growth.

Stocks Performance
O2T vs DAX Index

Loading
O2T
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
O2T vs DAX Index

Loading
O2T
DAX Index
Difference
www.alphaspread.com

Performance By Year
O2T vs DAX Index

Loading
O2T
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Iveric Bio Inc vs Peers

DAX Index
O2T
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Iveric Bio Inc
Glance View

Market Cap
59m EUR
Industry
Biotechnology

IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 37 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). The company is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The firm is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

O2T Intrinsic Value
Not Available
I
Back to Top